Presby Corp Hires Thomas M. Riedhammer as Chief Operating Officer - Announces Multiple Presentations at ASCRS Convention

Apr 19, 2001, 01:00 ET from Presby Corp

    DALLAS, April 19 /PRNewswire/ -- Presby Corp is pleased to announce that
 Thomas M. Riedhammer, Ph.D. has joined the Company as Chief Operating Officer.
 Dr. Riedhammer has over twenty-five years experience in the ophthalmic
 industry and was formerly Senior Vice President, Chief Technical Officer and
 President - Global Pharmaceuticals for Bausch & Lomb, Inc.  His former
 responsibilities included B&L's worldwide $350 million drug products business.
 As Chief Technical Officer, Dr. Riedhammer was responsible for B&L's global
 research & development activities including FDA clinical trials for a number
 of B&L's most successful products.  In the mid-90's, he managed B&L's
 worldwide Surgical & Hearing Care products businesses while based in Berlin,
 Germany.  Dr. Riedhammer's responsibilities will include Presby's global
 marketing, strategic alliances, FDA clinical trials and research and
 development activities.
     Presby is also pleased to note that at least fourteen speakers scheduled
 to present scientific papers at the upcoming American Society of Cataract and
 Refractive Surgery ("ASCRS") convention will feature Presby's Scleral
 Expansion Band Procedure ("SRP") for the Surgical Reversal of Presbyopia and
 the treatment of Ocular Hypertension and Primary Open Angle Glaucoma ("POAG").
 This year's ASCRS convention in San Diego is expected draw over
 10,000 international and domestic ophthalmologists.  Presentations at ASCRS
 include the latest information on medical advances in the field of ophthalmic
 surgery.
     Presby Corp has developed the Scleral Expansion Band Procedure ("SRP") for
 the treatment of Presbyopia, Ocular Hypertension and POAG.  Presbyopia is the
 inability to focus at near distances and the primary reason that nearly
 everyone after their mid-40's uses bifocals, reading glasses or removes their
 distance glasses in order to read clearly.  The Company believes that SRP
 physiologically restores the ability of the eye to accommodate or focus and
 also physiologically lowers intraocular pressure in patients with Ocular
 Hypertension and POAG.
     The SRP procedure utilizes a tiny implant device called a Scleral
 Expansion Band ("SEB") that is patented or patent pending virtually worldwide.
 The Company is currently conducting U.S. FDA and Canadian clinical trials of
 the SEB for treatment of Presbyopia.  Clinical trials for the treatment of
 Ocular Hypertension and POAG are ongoing in Canada and are expected to begin
 in the United States shortly.
     Presby Corp is based in Dallas, Texas.  For further information, visit the
 Company at www.presbycorp.com or contact Ronald A. Schachar, M.D., Ph.D.,
 Chairman & Chief Executive Officer, at 214/368-0200 (fax 214/368-0332) or
 email presby@presbycorp.com.
 
 

SOURCE Presby Corp
    DALLAS, April 19 /PRNewswire/ -- Presby Corp is pleased to announce that
 Thomas M. Riedhammer, Ph.D. has joined the Company as Chief Operating Officer.
 Dr. Riedhammer has over twenty-five years experience in the ophthalmic
 industry and was formerly Senior Vice President, Chief Technical Officer and
 President - Global Pharmaceuticals for Bausch & Lomb, Inc.  His former
 responsibilities included B&L's worldwide $350 million drug products business.
 As Chief Technical Officer, Dr. Riedhammer was responsible for B&L's global
 research & development activities including FDA clinical trials for a number
 of B&L's most successful products.  In the mid-90's, he managed B&L's
 worldwide Surgical & Hearing Care products businesses while based in Berlin,
 Germany.  Dr. Riedhammer's responsibilities will include Presby's global
 marketing, strategic alliances, FDA clinical trials and research and
 development activities.
     Presby is also pleased to note that at least fourteen speakers scheduled
 to present scientific papers at the upcoming American Society of Cataract and
 Refractive Surgery ("ASCRS") convention will feature Presby's Scleral
 Expansion Band Procedure ("SRP") for the Surgical Reversal of Presbyopia and
 the treatment of Ocular Hypertension and Primary Open Angle Glaucoma ("POAG").
 This year's ASCRS convention in San Diego is expected draw over
 10,000 international and domestic ophthalmologists.  Presentations at ASCRS
 include the latest information on medical advances in the field of ophthalmic
 surgery.
     Presby Corp has developed the Scleral Expansion Band Procedure ("SRP") for
 the treatment of Presbyopia, Ocular Hypertension and POAG.  Presbyopia is the
 inability to focus at near distances and the primary reason that nearly
 everyone after their mid-40's uses bifocals, reading glasses or removes their
 distance glasses in order to read clearly.  The Company believes that SRP
 physiologically restores the ability of the eye to accommodate or focus and
 also physiologically lowers intraocular pressure in patients with Ocular
 Hypertension and POAG.
     The SRP procedure utilizes a tiny implant device called a Scleral
 Expansion Band ("SEB") that is patented or patent pending virtually worldwide.
 The Company is currently conducting U.S. FDA and Canadian clinical trials of
 the SEB for treatment of Presbyopia.  Clinical trials for the treatment of
 Ocular Hypertension and POAG are ongoing in Canada and are expected to begin
 in the United States shortly.
     Presby Corp is based in Dallas, Texas.  For further information, visit the
 Company at www.presbycorp.com or contact Ronald A. Schachar, M.D., Ph.D.,
 Chairman & Chief Executive Officer, at 214/368-0200 (fax 214/368-0332) or
 email presby@presbycorp.com.
 
 SOURCE  Presby Corp